Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMKFUP)

Drug Name
Adatanserin Drug Info
Synonyms Adatanserin [INN]; WY 50324; N-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethyl]adamantane-1-carboxamide
Cross-matching ID
PubChem CID
130918
CAS Number
CAS 127266-56-2
TTD Drug ID
D0X2TO

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.18 0.00e+0 93/133 (69.92%) ATP6V1D;NDUFB5;ATP5MC2;...
Protein export 1.97 7.99e-3 17/23 (73.91%) OXA1L;SEC11A;SEC61B;...
Ribosome 1.96 5.32e-3 113/158 (71.52%) RPL36;RPL36AL;RSL24D1;...
Mineral absorption 1.87 9.98e-3 48/60 (80%) TF;MT1E;MT1F;...
Retinol metabolism 1.82 2.40e-2 41/68 (60.29%) UGT2B28;DHRS9;CYP3A5;...
Butanoate metabolism 1.79 2.26e-2 23/28 (82.14%) HMGCS2;EHHADH;HADH;...
alpha-Linolenic acid metabolism -1.71 4.67e-2 17/25 (68%) FADS2;PLA2G12A;PLA2G1B;...
Ribosome biogenesis in eukaryotes -1.72 4.79e-2 52/108 (48.15%) CSNK2A1;DROSHA;EFL1;...
Proteoglycans in cancer -1.79 3.00e-2 172/205 (83.9%) PPP1R12A;SOS2;TWIST1;...
Type II diabetes mellitus -1.82 2.57e-2 42/46 (91.3%) MTOR;SOCS3;ADIPOQ;...
Focal adhesion -1.84 2.20e-2 180/201 (89.55%) MAP2K1;EGFR;BIRC3;...
Amoebiasis -1.85 2.40e-2 99/102 (97.06%) GNA15;LAMA4;GNA11;...
Primary immunodeficiency -1.87 2.40e-2 33/38 (86.84%) CD4;LCK;RAG2;...
TNF signaling pathway -1.87 3.20e-2 103/112 (91.96%) TRAF5;CREB3;SOCS3;...
Protein digestion and absorption -1.91 4.79e-2 78/103 (75.73%) CTRB2;SLC36A1;CELA2A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H